Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, has announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share.
Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, has announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share. As detailed in the company’s press release, Prevail has granted the underwriters a 30-day option to purchase up to an additional 1,102,950 shares of its common stock at the initial public offering price less underwriting discounts and commissions.
Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili, with associates Justin McNamee and Jonathan Guest.
